Controversies in the Treatment of Wet Age-related Macular Degeneration

[...]Genentech has modified the molecule of bevacizumab without affecting the basis of its efficacy and now specifically addressed to treating this pathology. [...]ranibizumab was developed, it is forty times more expensive, although no indirect comparisons have proved significant differences betwee...

Ausführliche Beschreibung